ArticleBiomaterials2026
Scar-reducing ionically conductive chitosan bandage: Combining ionic and electrical stimulation for optimal wound healing.
Article in Biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chitosan-Based Wound Dressings: Property Modulation, Fabrication Strategies, and Emerging Applications in Tissue Regeneration.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Large, complex wounds frequently exhibit suboptimal healing, leading to scarring and functional impairment. While bioactive materials and electrical stimulation (ES) show promise, their individual limitations call for novel approaches. This study investigates the combined effects of combining 4-aminopyridine (4AP) and electrical stimulation (ES) on human dermal fibroblasts (hDFBs) using a stable, ionically conductive (IC) chitosan-based scaffold for controlled drug delivery. To enable sustained release of the highly water-soluble 4AP, halloysite nanotubes (HNT) were incorporated as secondary carriers within the bandage system. In vitro assays revealed that combining 4AP (100 ng/mL) with ES significantly enhanced hDFB metabolic activity, wound closure, and maintained mitochondrial function along with reduced inflammation under stress condition. Gene expression analysis showed upregulation of key extracellular matrix (ECM) and growth factor genes at day 7, followed by a shift to the remodeling phase by day 14 in vitro. Histological and immunohistochemical analyses revealed improved ECM organization, as indicated by an optimal collagen I/III ratio; enhanced angiogenesis (CD31); increased cellular activity (α-SMA, vimentin, Ki-67); and elevated expression of neurotrophic factors in the combined full-thickness wound treatment group. These findings highlight a potential additive mechanism, in which 4AP may enhance the effects of ES by supporting cellular metabolism. This integrated approach offers a promising, multifaceted strategy for improving dermal wound healing and minimizing scarring, warranting further in vivo investigation for clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.